Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42847922 safety, sleep, and biomarker study in major depressive disorder
NL-OMON42397Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of seltorexant in major depressive disorder (MDD) and Insomnia (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Latency to persistent sleep, Total sleep time and 5 more. Started Jul 2015; status: active, not recruiting.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NL-OMON42397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42397.